Lloyd Mayer - Concepedia

Author

Lloyd Mayer

Also Known As

Burks, A. Wesley, Burton I Korelitz, Dawson, Peter, Diana Kim, Galanko, Joseph, Harpaz, Noam, LLOYD F. MAYER, LLOYD MAYER, Lloyd F Mayer, Lloyd F. Mayer

279

Publications

25.4K

Citations

H-Index

139

Concepts

All Affiliations

Icahn School of Medicine at Mount Sinai Mount Sinai Medical Center Mount Sinai Hospital University of Chicago Cedars-Sinai Medical Center

About

Lloyd Mayer is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, immunology, and inflammation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	44	73	14.2K
2	Allergy	17	21	3K
3	Allergy Medicine	5	5	1K
4	Engineering	1	1	263
5	Natural Sciences	1	1	65

Lloyd Mayer

124

Publications

22.1K

Citations

H-Index

Page 1

	Year	Citations
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein, The Lancet InflammationChronic Inflammatory DiseasesAnti-inflammatoryMaintenance InfliximabGastroenterology	2002	4.1K
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease Daniel H. Present, Paul Rutgeerts, Stephan Targan, New England Journal of Medicine	1999	2.7K
Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Paul Rutgeerts, Geert D’Haens, Stephan R. Targan, Gastroenterology InflammationChronic Inflammatory DiseasesAnti-inflammatoryImmunologyGastroenterology	1999	1.1K
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease Paul Rutgeerts, Brian G. Feagan, Gary R. Lichtenstein, Gastroenterology InflammationEpisodic Treatment StrategiesAnti-inflammatoryCrohn ’Gastroenterology	2004	947
Anti–Interleukin-12 Antibody for Active Crohn's Disease Peter Mannon, Ivan J. Fuss, Lloyd Mayer, New England Journal of Medicine	2004	851
Mucus Enhances Gut Homeostasis and Oral Tolerance by Delivering Immunoregulatory Signals Meimei Shan, Maurizio Gentile, John R. Yeiser, Science Chronic Inflammatory DiseasesDysbiosisMucus BarrierMicrobial PathogensImmunology	2013	610
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease Stephen B. Hanauer, Carrie Wagner, Mohan Bala, Clinical Gastroenterology and Hepatology InflammationChronic Inflammatory DiseasesAutoimmune DiseaseAllergyCrohn ’	2004	606
The Incidence and Management of Infusion Reactions To Infliximab: A Large Center Experience Adam S. Cheifetz, Michelle V. Smedley, S Bogetz Martin, The American Journal of Gastroenterology	2003	487
The natural history of milk allergy in an observational cohort Robert A. Wood, Scott H. Sicherer, Brian P. Vickery, Journal of Allergy and Clinical Immunology NutritionFood AllergyAllergyAllergy MedicinePeanut Allergy	2012	468
Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study Bruce E. Sands, William J. Tremaine, William J. Sandborn, Inflammatory Bowel Diseases InflammationRheumatologyAnti-inflammatorySystemic TreatmentPlanned Patients	2001	427

Page 1